| |
|
Policy
An important aspect of the work of the National Research Center for Women & Families and our Cancer Prevention and Treatment Fund is to provide objective information to policy analysts, policy makers, and opinion leaders. As we collect and analyze scientific data on the effectiveness of programs and services affecting the health and safety of adults and children, we determine the policy implications and share our findings in Issue Briefs, reports, meetings, and testimony before Congress, the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), and other agencies at the federal, state, and local level. You can find examples of our official statements and reports posted to this Policy section of our website as they are released.
If you have any questions, please contact Paul Brown at 202 223-4000 or pb@center4research.org. Testimony before Congress, Parliament, or the FDA
November 12, 2009
Testimony of Dr. Diana Zuckerman to the FDA Public Hearing on Promotion of Medical Products via the Internet and Social Media
June 24, 2009
Testimony of Dr. Diana Zuckerman to the FDA on Transparency
June 9, 2009
Statement of Diana Zuckerman before the FDA Psychopharmalogic Drugs Advisory Committee on Seroquel, Zyprexa and Geodon PDF version
April 9, 2009
Testimony of Dr. Diana Zuckerman before DC Health Committee, on HPV
April 8, 2009
Testimony of Dr. Diana Zuckerman on Seroquel XR at the FDA Psychopharmacologic Drugs Advisory Committee meeting
February 24, 2009
Statement of
Diana Zuckerman at the FDA Science Board Meeting on the Use of Bisphenol
A in Food Containers
January 29, 2009
Statement of Diana
Zuckerman regarding food safety before the USDA Dietary Guidelines
Advisory Committee
October 31, 2008
Statement of
Diana Zuckerman at the FDA Science Board Meeting on the FDA Draft
Assessment of Bisphenol A for Use in Food Contact Applications
October 2, 2008
Statement of Diana Zuckerman At the FDA Part 15 Hearing Over the Counter Cough and Cold Medications for Pediatric Uses
September 16, 2008
Statement of Diana Zuckerman to the FDA Science Board on the FDA Draft Assessment of Bisphenol A (BPA) in Food Containers
September 8, 2008
Statement of Diana Zuckerman
Regarding Fablyn Before the FDA Advisory Committee on Reproductive
Drugs
June 12, 2007
Statement
of Diana Zuckerman Regarding FDA Legislation Before the Subcommittee
on Energy and Commerce, June 12, 2007
April 25, 2008
Statement of Diana Zuckerman At the FDA Advisory Panel Meeting Regarding LASIK Devices
Testimony,
Statements and Public Comments
March 9, 2007
Statement on the Safety of Medical Products
January 26, 2007
Statement of Diana Zuckerman, Ph.D.,
President, National Research Center for Women & Families At the
FDA Advisory Panel Meeting, Regarding the NeuroStar TMS System
for Major Depression
November, 2006
Joint Statement of Science, Public Health, and Consumer Groups
November, 2006
Changes Needed to Improve Nutrition of WIC Foods
September, 2006
Enhancing Drug Safety
and Innovation Act
Policy Archives
Testimony, Statements
and Public Comments
June 8, 2006
Invited
Testimony of Diana Zuckerman, PhD, Before the Standing Committee
on Health, Canadian Parliament, Ottawa, June 8, 2006
September, 2005
Statement
of Dr. Diana Zuckerman, President of National Research Center
for Women & Families, On FDA 'Approvable' Letter for Breast Implant
Manufacturer
July, 2005
Statement
of Dr. Diana Zuckerman, President of National Research Center
for Women & Families, Regarding the FDA Breast Implant Decision
April, 2005
FDA
Panel Votes 7-To-2 To Lift Restrictions On Mentor's Silicone Breast
Implants, With Unusually Large Number Of Post-Market Conditions
February 17, 2005
Protecting
Patients from Long-term Risks
February 2, 2005
State
of the Union and Social Security
September, 2004
Testimony
Before the Institute of Medicine On Review of the WIC Food Packages,
Diana Zuckerman, Ph.D
September, 2004
Statement
of Diana Zuckerman, Ph.D., to the FDA Regarding Suicide and the
Use of Antidepressants by Children
March, 2004
Statement
of Diana Zuckerman, Ph.D., Regarding the FDA/EPA Dietary Advisory
on Methylmercury in Fish
December, 2003
Statement
of Diana Zuckerman, Ph.D., to the FDA Food Advisory Committee
on Methylmercury
November, 2003
Testimony
Before the FDA on Hylaform, Diana Zuckerman, Ph.D
November, 2003
Testimony
Before the FDA on Restylane, Diana Zuckerman, Ph.D
October, 2003
Statement
of Diana Zuckerman, Ph.D., to the FDA Regarding Silicone Gel
Breast Implants
May, 2003
National
Medical Association and the CPR for Women & Families' letter to
the FDA regarding Artecoll
April, 2003
Comment
On Medwatch: The FDA Medical Products Reporting Program
April, 2003
Comment
On Dietary Supplements Containing Ephedrine
March, 2003
Comment
On FDA Guidance For Industry Collection Of Race and Ethnicity Data
in Clinical Trials
February, 2003
Testimony
Before the FDA On Artecoll, Diana Zuckerman, Ph.D
February, 2003
Testimony
Before the FDA On Artecoll, Elizabeth Nagelin-Anderson, MA
September, 2002
Public
Comment Letter to the FDA on Misleading Ads
July, 2002
Statement of Diana Zuckerman,
Ph.D., Before the FDA's Food Advisory Committee Meeting on Methylmercury,
July 24, 2002
July, 2002
FDA
Panel SLAMS Breast Implant Safety Data
July, 2002
Testimony
of Diana Zuckerman, PhD at the Meeting of The FDA Advisory Committee
on Saline Breast Implants, July 9, 2002
July, 2002
Testimony
of Jae Hong Lee, MD, MPH at the Meeting of the FDA Advisory Committee
on Saline Breast Implants, July 9, 2002
May, 2001
Statement
of Diana Zuckerman, Ph.D., President, National Center for Policy
Research for Women & Families Regarding the Breast Implant Research
and Information Act at the US Capitol May 24, 2001 Press Conference
March, 2001
Senate Policy Forum on
Women and Families
December, 2000
How the FDA Can Better
Protect Consumers
September, 2000
FDA
Warns of Dangers of Breast Implants
October, 2000
Unnecessary
Mastectomy Common in US
May, 2000
Statement of Diana Zuckerman
on the Panty Raider Computer Game
|
|
|
